FTH1 (Ferritin Heavy Chain 1) is a fundamental iron-storage protein that plays a critical role in maintaining iron homeostasis in the brain. As part of the ferritin heteropolymer, FTH1 is essential for sequestering excess iron and preventing iron-mediated oxidative damage, a key contributor to neurodegenerative processes. [@fthftl]
FTH1 (Ferritin Heavy Chain 1) is a fundamental iron-storage protein that plays a critical role in maintaining iron homeostasis in the brain. As part of the ferritin heteropolymer, FTH1 is essential for sequestering excess iron and preventing iron-mediated oxidative damage, a key contributor to neurodegenerative processes. [@fthftl]
Neuroprotection: Supports neuronal survival under oxidative stress conditions
Myelin Maintenance: Essential for oligodendrocyte function and myelin synthesis
Dendritic Iron Regulation: Modulates iron levels in dendritic processes
FTH1 is highly expressed in [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), and oligodendrocytes, with particularly high levels in the substantia nigra and basal ganglia.
Role in Neurodegeneration
Alzheimer's Disease (AD)
Iron accumulation: Elevated iron levels in amyloid plaques and neurofibrillary tangles correlate with FTH1 upregulation
Oxidative stress: Dysregulated iron homeostasis contributes to [amyloid-beta](/proteins/amyloid-beta) toxicity
Therapeutic implications: Ferritin levels in cerebrospinal fluid serve as a biomarker for AD progression
Parkinson's Disease (PD)
Neuromelanin interaction: FTH1 interfaces with neuromelanin in the substantia nigra
Iron dysregulation: Post-mortem studies show increased ferritin in PD brains
Substantia nigra vulnerability: Region-specific iron accumulation parallels dopaminergic neuron loss
Neuroferritinopathy
Autosomal dominant disorder: Caused by FTH1 mutations affecting iron storage
Basal ganglia degeneration: Leads to chorea, dystonia, and cognitive decline
Ferroxidase dysfunction: Mutations impair iron oxidation and storage capacity
Other Neurodegenerative Conditions
Amyotrophic Lateral Sclerosis (ALS): Altered ferritin levels in motor neurons
Friedreich's Ataxia: Interaction with frataxin deficiency affects iron metabolism
Huntington's Disease: Dysregulated iron homeostasis contributes to pathology
Therapeutic Targeting
Current therapeutic approaches targeting FTH1 and iron metabolism include:
| Agent | Mechanism | Status | |-------|-----------|--------| | Deferoxamine | Iron chelation | Clinical trials for AD/PD | | Deferasirox | Oral iron chelator | Investigational for PD | | Clioquinol | Metal-protein attenuating compound | Phase II for AD | | M30 | Iron chelator with neuroprotective activity | Preclinical |
Key Publications
[Connor et al., Ferritin in the aging brain (1992)](https://doi.org/10.1016/0197-4580(92)90067-6)
[Quintana et al., Iron and Parkinson's disease (2006)](https://doi.org/10.1016/j.jns.2006.03.023)
[Cozzi et al., Neuroferritinopathy mutations (2013)](https://doi.org/10.1093/brain/aws343)
[Wang et al., Ferritin in Alzheimer's disease (2021)](https://doi.org/10.1186/s13024-021-00450-7)
[Schmuck et al., Iron chelation therapy in neurodegeneration (2022)](https://doi.org/10.1007/s00018-022-08219-5)
Related Pages
[FTH1 Gene](/genes/fth1)
[Iron Metabolism in Neurodegeneration](/mechanisms/iron-metabolism-neurodegeneration)